EFFECTIVENESS OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: A COMBINED ANALYSIS OF REAL-WORLD EVIDENCE

被引：0
作者：
Cummings, Fraser
Buisson, Anthony
Smith, Philip J.
Rahmany, Sohail
Subramanian, Sreedhar
Kwon, Buki
Park, Soyeon
Lee, Young Nam
Fumery, Mathurin
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1854
引用
收藏
页码：S1144 / S1144
页数：1
相关论文
共 50 条
  • [21] EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. REAL-LIFE EVIDENCE FROM ENEIDA REGISTRY
    Iborra, Marisa
    Marin, Alejandro Garrido
    Oliva, Berta Caballol
    Huguet, Jose Maria
    Garcia, Lara Arias
    Mesonero, Francisco
    Fernandez-Prada, Samuel J.
    Watts, Marta M. Bosca
    Diaz, Angel Ponferrada
    Calvet, Xavier
    Gutierrez, Ana
    Ordas, Ingrid
    Ruiz-Sanchez, Lucia
    Sicilia, Beatriz
    de la Filia, Irene Garcia
    Domenech, Eugeni
    Nos, Pilar
    GASTROENTEROLOGY, 2023, 164 (06) : S95 - S95
  • [22] MULTIPLE BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH DISEASE FLARE IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL US COHORT
    Hou, Jason
    Pham, Codey
    Xu, Anthony
    Sansgiry, Shubhada
    Modi, Varsha
    Waljee, Akbar
    GASTROENTEROLOGY, 2024, 166 (03) : S9 - S9
  • [23] Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease
    Volkers, A.
    Straatmijer, T.
    Duijvestein, M.
    Sales, A.
    Levran, A.
    van Schaik, F.
    Jeroen, M.
    Gecse, K.
    Ponsioen, C.
    Grootjans, J.
    Hanzel, J.
    Tack, G.
    Jansen, J.
    Hoentjen, F.
    de Boer, N.
    van der Marel, S.
    Dijkstra, G.
    Oldenburg, B.
    Lowenberg, M.
    van der Meulen, A.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I108 - I109
  • [24] MULTIPLE BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH DISEASE FLARE IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL US COHORT
    Hou, Jason
    Pham, Codey
    Xu, Anthony
    Sansgiry, Shubhada
    Modi, Varsha
    Waljee, Akbar
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S7 - S7
  • [25] PRECISION DOSING TEST IN OPTIMIZING INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EVIDENCE STUDY
    Abraham, Bincy P.
    Fatima, Ayesha
    Battat, Robert J.
    Carroll, Kristin
    Torres, Esther A.
    Rabizadeh, Shervin
    Ziring, David
    Gohndrone, Judith
    Lum, Donald
    Arai, Ronen
    Ali, Tauseef
    Allen, Mark J.
    Condino, Adria A.
    Stein, Daniel J.
    Pandey, Akash
    Barrett, Terrence
    Ritter, Timothy E.
    Bray, Harry
    Hanauer, Stephen B.
    Dervieux, Thierry
    Colombel, Jean Frederic
    GASTROENTEROLOGY, 2023, 164 (06) : S1111 - S1111
  • [26] Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission
    Parisio, Laura
    Settanni, Carlo Romano
    Varca, Simone
    Laterza, Lucrezia
    Lopetuso, Loris Riccardo
    Napolitano, Daniele
    Schiavoni, Elisa
    Turchini, Laura
    Fanali, Caterina
    Alfieri, Norma
    Pizzoferrato, Marco
    Papa, Alfredo
    Pafundi, Pia Clara
    Armuzzi, Alessandro
    Gasbarrini, Antonio
    Pugliese, Daniela
    Scaldaferri, Franco
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2023, 32 (04) : 452 - 459
  • [27] From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative
    Verma, Ajay M.
    Patel, Anusha
    Subramanian, Sreedhar
    Smith, Philip J.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (02): : 88 - 89
  • [28] Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study
    Buisson, Anthony
    Nachury, Maria
    Pereira, Bruno
    Fumery, Mathurin
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (05) : 1127 - 1129
  • [29] Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial
    Schreiber, Stefan
    D'Haens, Geert
    Cummings, Fraser
    Irving, Peter M.
    Ye, Byong Duk
    Ben-Horin, Shomron
    Kim, Dong-Hyeon
    Jeong, Ae Lee
    Reinisch, Walter
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (07) : 1204 - 1212
  • [30] Real-world experience of subcutaneous infliximab use in children with inflammatory bowel disease (IBD) at a tertiary paediatric centre
    Eldredge, J.
    Kaur, R.
    Tano, M.
    Chidgey, T.
    Singh, N.
    Chuah, C. W.
    Magoffin, A.
    Thacker, K.
    O'Loughlin, E.
    Dutt, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1832 - i1833
12345